-1200x645-800x430.jpg)
- Novel immune activation approach shown in ex vivo and in vivo experiments
- Builds on breakthrough immune system discovery
- Market projected to reach US$185 billion by 2035
Noxopharm (ASX:NOX) has jumped by 40% after it obtained new data showing how the Sofra technology platform will be leveraged to fight cancer.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more
Sofra technology has been identified to have potential applications in a wide range of diseases related to the immune system such as rheumatoid arthritis, lupus and diabetes, as well as other diseases like cancer.
CEO, Dr Olivier Laczka, said the field of immuno-oncology, which involves harnessing the body’s own immune system to destroy cancer cells, has reshaped cancer treatment over recent years and helped millions of patients.
“We are very encouraged by these results and the potential of the Sofra platform in the cancer space. Our deep and novel understanding of how innate immune receptors such as TLR8 are naturally regulated provides a unique advantage in targeting them,” Dr Laczka said,
“Our immuno-oncology program is built on a robust foundation of molecular and mechanistic understanding, and is an excellent example of how we translate fundamental biology into new therapeutic opportunities.
“With our strong background in oncology and immune-modulating drug development, our data supports a new and different approach to addressing significant unmet needs in cancer treatment, paving the way for a potentially highly disruptive new treatment modality.”
Dr Laczka said the market is projected to grow from US$35 billion in 2025 to US$185 billion by 2035.
“However, response rates remain limited and there is an ongoing need for new approaches.”
Toll-like receptors (TLRs) are crucial sensors within the human immune system. Their activation is a primary area of cancer research, with numerous pharmaceutical companies developing potent anti-cancer agents based on these receptors and having them approved.
Noxopharm is currently advancing a drug development program aimed at harnessing the power of Toll-like receptor 8 (TLR8) against cancer. The company has now developed oligonucleotides capable of greatly amplifying the activity of TLR8 compared to current best- in-class drugs in clinical development, which in turn stands to enhance the cancer-fighting activity of standard-of-care therapies like chemotherapy and radiotherapy.
Dr Laczka said this combinatorial approach opens up a new opportunity for more potent, controllable and targeted activation of the immune system against cancer, exploiting a novel mechanism that was uncovered through in-depth studies of TLR8 biology.
“This places the innovative technology, which is protected by a granted US patent, in a key position to unlock the clinical potential of TLR8 activation in immuno-oncology and potentially become a competitive new addition to the global cancer treatment market.”
NOX is up 40% to 8.4¢. Mkt cap $18.43M.
Join the discussion: See what HotCopper users are saying about Noxopharm and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.